Biosimilar Development News

31. Celltrion Healthcare Presents Positive One-Year Data For The First High-Concentration, Low-Volume And Citrate-Free Biosimilar Adalimumab, Yuflyma (CT-P17) In Patients With Rheumatoid Arthritis At EULAR 2021 6/1/2021

    Celltrion Healthcare today presented positive results from the Phase III CT-P17 3.1 trial comparing the efficacy and safety of biosimilar adalimumab,Yuflyma, with reference adalimumab in patients with active rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology 2021 (EULAR Virtual Congress 2021).

32. Biogen And Bio-Thera Announce Positive Results From Phase 3 Study Of BAT1806, A Proposed Biosimilar Referencing Actemra® (Tocilizumab) 6/1/2021

    Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing ACTEMRA®/RoACTEMRA® (tocilizumab).

33. Prime Therapeutics Launches MedDrive™, A First-Of-Its Kind Medical Drug Management Program Uniquely Aligned With Its Blue Plan Clients 5/28/2021

    Today, Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM) serving nearly 33 million members across 23 Blue Plans, unveiled MedDrive™ a new medical drug management program that provides solutions to help its Blue Plan clients manage the high costs associated with medically billed drugs

34. New White Paper Identifies Patent Thickets As Barrier To US Biosimilars Market And Domestic Manufacturing 5/28/2021

    Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name ‘Ujvira’.

35. BioFactura Announces Initiation Of Phase I Study Of BFI-751, A Stelara (ustekinumab) Biosimilar 5/25/2021

    BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera

36. Zydus Launches Ujvira (Trastuzumab Emtansine), A Breakthrough In Breast Cancer Treatment 5/24/2021

    Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name ‘Ujvira’.

37. Quebec Announces Intention To Implement A Biosimilar Switching Policy 5/19/2021

    Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian Dubé for announcing the province's intention to implement a biosimilar switching policy under its public prescription drug insurance plan.

38. Sandoz Canada Congratulates The Quebec Government On Implementing A Shift Towards Biosimilars 5/18/2021

    Sandoz Canada, a leader in generic pharmaceuticals and biosimilars, welcomes the Quebec Government’s shift towards biosimilars. According to the government’s announcement, this transition will generate annual savings of more than $100 for the public drug insurance plan and its insured parties.

39. House Oversight Committee Spotlights Anticompetitive Practices Blocking Access To Lower Cost Biosimilars 5/18/2021

    The U.S. House Oversight and Reform Committee today held a hearing that highlighted the need for biosimilar competition to bring down health care costs.

40. Sandoz Canada Launches Its 6th Biosimilar With Inclunox® And Inclunox® HP (Enoxaparin Sodium Solution For Injection 100 mg/mL And 150 mg/mL (High Potency)) 5/18/2021

    Sandoz Canada Inc. announced today the launch of PrInclunox® and PrInclunox® HP (enoxaparin sodium solution for injection, reference biologic drug: Sanofi’s PrLovenox® and PrLovenox® HP), which was authorized for sale in Canada by Health Canada on November 5, 2020.